Physician profile
Michael Sonabend
NPI 1578696936
$183,772.31
in general payments reported to CMS, 2019-2025
42 companies · $23K in 2025
The $23K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $11K · 2021: $19K · 2022: $41K · 2023: $40K · 2024: $28K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $68K · Food and Beverage: $15K · Consulting Fee: $3,969 · Travel and Lodging: $3,528 · Education: $290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $67,896.50 |
| Food and Beverage | $14,690.00 |
| Consulting Fee | $3,969.00 |
| Travel and Lodging | $3,527.73 |
| Education | $289.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $155,985.80 | 2019-2025 | Skyrizi, Rinvoq, Botox |
| Novartis Pharmaceuticals Corporation | $5,864.11 | 2019-2025 | |
| Genzyme Corporation | $3,487.06 | 2019-2025 | |
| Janssen Biotech, INC. | $2,653.11 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $1,817.79 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $1,815.84 | 2019-2025 | Dupixent, Libtayo |
| Incyte Corporation | $1,643.50 | 2021-2025 | Opzelura |
| Allergan, INC. | $1,579.02 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $1,172.78 | 2019-2025 | Ilumya |
| Ucb, INC. | $1,082.73 | 2019-2025 | Bimzelx, Cimzia |
| Amgen INC. | $957.28 | 2019-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $806.14 | 2022-2025 | Sotyktu |
| Biofrontera INC. | $685.33 | 2019-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Pfizer INC. | $586.07 | 2019-2025 | |
| Leo Pharma INC. | $577.93 | 2019-2025 | Adbry, Anzupgo |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Sonabend listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.